Influenza Clinical Trial
Official title:
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Verified date | March 2017 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational vaccine GSK2321138A in children aged 3 to 17 years, and to describe safety and immunogenicity of the GSK Biologicals' investigational vaccine GSK2321138A in children aged 6 to 35 months.
Status | Completed |
Enrollment | 3027 |
Est. completion date | June 15, 2011 |
Est. primary completion date | June 15, 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months to 17 Years |
Eligibility |
Inclusion Criteria: - Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol. - For non US countries: - - Children, male or female, aged between 6 months and 17 years at the time of the first study vaccination. For US : - Children, male or female, aged between 3 and 17 years at the time of the first study vaccination - Written informed consent obtained from the subject parent(s) or LAR(s) of the subject. Assent obtained from the subject when applicable. - Subjects in stable health as determined by investigator's clinical examination and assessment of subjects' medical history. - Written informed assent obtained from the subject if/as required by local regulations. - Female subjects of non-childbearing potential may be enrolled in the study. - Female subjects of childbearing potential may be enrolled in the study, if the subject: - - has practiced adequate contraception for 30 days prior to vaccination, - - and has a negative urine pregnancy test on the day of vaccination, - - and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series Exclusion Criteria: - Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period. Routine registered childhood vaccinations are permitted. - Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration. - Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination. - Prior receipt of any seasonal or pandemic influenza vaccine (registered or investigational) within 6 months preceding the first dose of study vaccine, or planned use during the study period. - Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period. - Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned during the study. - Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination. - History of seizures or progressive neurological disease. - History of Guillain-Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine. - Concurrently participating in another clinical study, at any time during the study period in which the subject has been or will be exposed to an investigational or a non-investigational product . - History of hypersensitivity to a previous dose of influenza vaccine, history of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines - Acute disease and/or fever at the time of enrolment - Ongoing aspirin therapy - Pregnant or lactating female - Female planning to become pregnant or planning to discontinue contraceptive precautions. - Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study - Child in Care. |
Country | Name | City | State |
---|---|---|---|
Czechia | GSK Investigational Site | Decin | |
Czechia | GSK Investigational Site | Humpolec | |
Czechia | GSK Investigational Site | Jindrichuv Hradec | |
Czechia | GSK Investigational Site | Kolin | |
Czechia | GSK Investigational Site | Nachod | |
Czechia | GSK Investigational Site | Odolena voda | |
Czechia | GSK Investigational Site | Pardubice | |
Czechia | GSK Investigational Site | Plzen | |
Czechia | GSK Investigational Site | Praha 6 | |
Czechia | GSK Investigational Site | Tabor | |
France | GSK Investigational Site | Aix en Provence | |
France | GSK Investigational Site | Draguignan | |
France | GSK Investigational Site | Essey les Nancy | |
France | GSK Investigational Site | La Bouexiere | |
France | GSK Investigational Site | Le Havre | |
France | GSK Investigational Site | Nantes | |
France | GSK Investigational Site | Nice | |
France | GSK Investigational Site | Seysses | |
France | GSK Investigational Site | Tours | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Eschwege | Hessen |
Germany | GSK Investigational Site | Ettenheim | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Flensburg | Schleswig-Holstein |
Germany | GSK Investigational Site | Gilching | Bayern |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Heiligenhaus | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Kehl | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Kirchheim | Bayern |
Germany | GSK Investigational Site | Kleve-Materborn | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Leipzig | Sachsen |
Germany | GSK Investigational Site | Muenchen | Bayern |
Germany | GSK Investigational Site | Noerdlingen | Bayern |
Germany | GSK Investigational Site | Schwaebisch-Hall | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Solingen | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Stuttgart | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Tauberbischofsheim | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Trier | Rheinland-Pfalz |
Germany | GSK Investigational Site | Tuttlingen | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Weimar | Thueringen |
Germany | GSK Investigational Site | Willich | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Wolfenbuettel | Niedersachsen |
Philippines | GSK Investigational Site | Dasmariñas, Cavite | |
Philippines | GSK Investigational Site | Quezon City | |
United States | GSK Investigational Site | Binghamton | New York |
United States | GSK Investigational Site | Boca Raton | Florida |
United States | GSK Investigational Site | Boston | Massachusetts |
United States | GSK Investigational Site | Elmira | New York |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Lexington | Kentucky |
United States | GSK Investigational Site | Metairie | Louisiana |
United States | GSK Investigational Site | Omaha | Nebraska |
United States | GSK Investigational Site | Raleigh | North Carolina |
United States | GSK Investigational Site | Sacramento | California |
United States | GSK Investigational Site | San Angelo | Texas |
United States | GSK Investigational Site | Syracuse | New York |
United States | GSK Investigational Site | Wichita | Kansas |
United States | GSK Investigational Site | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States, Czechia, France, Germany, Philippines,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease. | Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Primary | Number of Seroconverted Subjects Against 4 Strains of Influenza Disease. | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer < 1:10 and a post-vaccination titer =1:40, or a pre-vaccination titer =1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). | At Day 28 (for primed subjects) and Day 56 (for unprimed subjects) | |
Secondary | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata. | Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years. |
At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata. | Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months. |
At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroconverted Subjects Against 4 Strains of Influenza Disease by Age Strata. | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer < 1:10 and a post-vaccination titer =1:40, or a pre-vaccination titer =1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years. | At Day 28 (for primed subjects) and Day 56 (for unprimed subjects) | |
Secondary | Number of Seroconverted Subjects Against 4 Strains of Influenza Disease by Age Strata. | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer < 1:10 and a post-vaccination titer =1:40, or a pre-vaccination titer =1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months. | At Day 28 (for primed subjects) and Day 56 (for unprimed subjects) | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza Disease | A seroprotected subject was defined as a vaccinated subject who had a serum HI titer = 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata. | A seroprotected subject was defined as a vaccinated subject who had a serum HI titer = 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years. | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata. | A seroprotected subject was defined as a vaccinated subject who had a serum HI titer = 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months. | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza. | A seroprotected subject was defined as a vaccinated subject who had a serum HI titer = 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata. | A seroprotected subject was defined as a vaccinated subject who had a serum HI titer = 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years. | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata. | A seroprotected subject was defined as a vaccinated subject who had a serum HI titer = 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months. | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza Disease. | A seroprotected subject was defined as a vaccinated subject who had a serum HI titer = 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata. | A seroprotected subject was defined as a vaccinated subject who had a serum HI titer = 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years. | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata. | A seroprotected subject was defined as as a vaccinated subject who had a serum HI titer = 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6 -17 months and 18-35 months. | At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST] | |
Secondary | Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease. | MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). | At Day 28 (for primed subjects) and Day 56 (for unprimed subjects) | |
Secondary | Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata. | MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years. | At Day 28 (for primed subjects) and Day 56 (for unprimed subjects) | |
Secondary | Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata. | MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6 -17 months and 18-35 months. | At Day 28 (for primed subjects) and Day 56 (for unprimed subjects) | |
Secondary | Number of Subjects With Any and Grade 3 Solicited Local Symptoms. | Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = Cried when limb was moved/spontaneously painful (Child <6 years) or pain that prevented normal activity (Child >6 years). Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of the injection site. | During the 7-day (Days 0-6) follow-up period after any vaccination. | |
Secondary | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Younger Than 6 Years Old. | Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = temperature >39.0°C. | During the 7-day (Days 0-6) follow-up period after any vaccination. | |
Secondary | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Aged 6 Years or Older. | Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = temperature >39.0°C. | During the 7-day (Days 0-6) follow-up period after any vaccination. | |
Secondary | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs). | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination. | During the 28-day (Days 0-27) follow-up period after any vaccination. | |
Secondary | Number of Subjects With Any, Grade 3 and Related Medically Attended Adverse Events (MAEs). | MAEs were defined as AEs that resulted in medical attention (defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason). Any = any MAE regardless of intensity or relationship to vaccination. Grade 3 MAE = MAE which prevented normal, everyday activities. Related = MAE assessed by the investigator as related to the vaccination. Assessment of intensity for MAEs was not performed. | During the entire study period (Day 0 - Day 180) | |
Secondary | Number of Subjects With Any and Related Potential Immune-Mediated Diseases (pIMDs). | pIMDs were defined as a subset of AEs that included both clearly autoimmune diseases (AID) and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. | During the entire study period (Day 0 - Day 180) | |
Secondary | Number of Subjects With Any and Related Serious Adverse Events (SAEs). | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. | During the entire study period (Day 0 - Day 180) | |
Secondary | Number of Days With Solicited Local Symptoms. | The number of days with any grade of local symptoms after Dose 1 and Dose 2 vaccination respectively was tabulated. Assessed solicited local symptoms for duration were pain, redness and swelling at the injection site. | During the 7-day (Days 0-6) follow-up period after vaccination. | |
Secondary | Number of Days With Solicited General Symptoms | The number of days with any grade of local symptoms after Dose 1 and Dose 2 vaccination respectively was tabulated. Assessed solicited general symptoms for duration were drowsiness, fatigue, gastrointestinal symptoms (Gastro.), headache, irritability, loss of appetite, muscle aches, shivering and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. | During the 7-day (Days 0-6) follow-up period after vaccination. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |